검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant chemoradiotherapy (Adjuvant chemoradiotherapy) University of Manitoba·Esophageal Cancer ORR 40% |
|---|---|
Overview Program | Adjuvant chemoradiotherapy |
Overview Company | University of Manitoba |
Overview Modality | ANTIBODY |
Overview Target | Esophageal Cancer |
Overview Indication | Esophageal Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | target epithelial-mesenchymal transition through the Wnt/β-catenin/TCF7 signaling pathway |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.. Completion total mesorectal excision (cTME) after local excision of early rectal cancer is associated with substantial morbidity and impaired functional outcomes. This study aimed to assess the oncologic… |
Clinical Primary efficacy | ORR 40% |
Clinical ORR | 40% |
Clinical OS | 20.27 |
Clinical Result source | ClinicalTrials.gov NCT01390948 |
Clinical Data Tier / Score | A · 46 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant chemoradiotherapy (Adjuvant chemoradiotherapy) University of Manitoba·Esophageal Cancer ORR 40% |
|---|---|
Overview Program | Adjuvant chemoradiotherapy |
Overview Company | University of Manitoba |
Overview Modality | ANTIBODY |
Overview Target | Esophageal Cancer |
Overview Indication | Esophageal Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | target epithelial-mesenchymal transition through the Wnt/β-catenin/TCF7 signaling pathway |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.. Completion total mesorectal excision (cTME) after local excision of early rectal cancer is associated with substantial morbidity and impaired functional outcomes. This study aimed to assess the oncologic… |
Clinical Primary efficacy | ORR 40% |
Clinical ORR | 40% |
Clinical OS | 20.27 |
Clinical Result source | ClinicalTrials.gov NCT01390948 |
Clinical Data Tier / Score | A · 46 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교